Resting and evoked spinal substance P release during chronic intrathecal morphine infusion: parallels with tolerance and dependence.
about
The mechanism of μ-opioid receptor (MOR)-TRPV1 crosstalk in TRPV1 activation involves morphine anti-nociception, tolerance and dependenceOpioid-receptor-heteromer-specific trafficking and pharmacology.Increased morphine analgesia and reduced side effects in mice lacking the tac1 gene.Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing two penicillaminesExpression of mu opioid receptor in dorsal diencephalic conduction system: new insights for the medial habenula.Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance.5-hydroxytryptamine type 3 receptor modulates opioid-induced hyperalgesia and tolerance in mice.Fluence-dependent effects of low-level laser therapy in myofascial trigger spots on modulation of biochemicals associated with pain in a rabbit model.Regulation of spinal substance p release by intrathecal calcium channel blockade.The beta2 adrenergic receptor regulates morphine tolerance and physical dependence.Improving metabolic stability by glycosylation: bifunctional peptide derivatives that are opioid receptor agonists and neurokinin 1 receptor antagonistsDesign, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists.Mechanisms of PDGF siRNA-mediated inhibition of bone cancer pain in the spinal cord.The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.Effects of intrathecal SNC80, a delta receptor ligand, on nociceptive threshold and dorsal horn substance p release.Spinal N-methyl-D-aspartate receptors and nociception-evoked release of primary afferent substance P.A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles.Gene therapy for pancreatitis pain.The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety.Polyanalgesic consensus conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel.Current and Future Issues in the Development of Spinal Agents for the Management of Pain.Neurokinin 1 and opioid receptors: relationships and interactions in nervous system.Long-Term Antihyperalgesic and Opioid-Sparing Effects of 5-Day Ketamine and Morphine Infusion ("Burst Ketamine") in Diabetic Neuropathic Rats.Preprotachykinin-A gene disruption attenuates nociceptive sensitivity after opioid administration and incision by peripheral and spinal mechanisms in mice.Decreased mu-opioid receptor signalling and a reduction in calcium current density in sensory neurons from chronically morphine-treated mice.Transgene-mediated enkephalin expression attenuates signs of naloxone-precipitated morphine withdrawal in rats with neuropathic pain.
P2860
Q26801420-AF6B548F-BAAE-474E-9F2C-A9BFC37A6364Q33978499-E6DAEAFD-09B0-4969-87B6-9A7655B5B3A2Q34124840-AD6B87DB-A165-450B-8BCF-92F81EF788CAQ34145341-CDB54BBD-4ADE-4067-B6F9-0747DB32CF8DQ34183878-32D26CB3-CC4B-46FD-A108-22A7EDAFA2D2Q34388992-19C46FC2-9007-468B-A093-7E2775B8223EQ34900986-1A6A4C97-4D51-444E-9FC2-BA73766905BBQ35239207-5F8D2262-18E9-4C28-8248-ABEDF8CF4D2FQ35988886-723DC1D8-141C-4890-B340-E53658DA7403Q36008573-EAD2684D-5F96-4A5D-BC3C-AC94419CB0A2Q36464821-63C32AF5-84EC-4F73-A658-D19470344152Q36628309-C675F8C5-3D72-423D-B971-70F6C57D760FQ36990758-25D1ACEF-70E9-4191-ADA6-B12CCE8677EEQ37176219-45B65586-08E5-4690-AEB7-F20769A7A895Q37252030-415854FA-7C64-4E9B-BE31-F13AA0DF1837Q37314774-78DF3796-E0FD-4D3E-9C8A-548E91DED15DQ37333022-62A9CD8D-725E-4701-BCAF-7CA143FD4ECFQ37365405-EFBF3A72-52E6-42FB-BABD-815C857AD82BQ37406982-B099454A-878D-46E3-AE6C-48BF659F4972Q37417012-349EBE32-BEE9-498C-AF91-103CD65FEC3DQ37965868-CD17EF9C-EB41-4114-8E59-1A88CBA19659Q38727831-43132E49-A33C-45A5-B48E-B69BB62EAC20Q38926264-A2C21057-27B9-471F-AE59-5C01D487AB09Q39192127-3FB11BB6-A129-4F84-8331-DB579EBF3B43Q41440089-C6FB7399-AAB7-4489-9AEA-244D1630BFDAQ41847530-5F20927F-19CD-4628-993E-685262D980AFQ41921009-9323BAB4-18EC-4A2B-A33F-F8DE03998A69
P2860
Resting and evoked spinal substance P release during chronic intrathecal morphine infusion: parallels with tolerance and dependence.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Resting and evoked spinal subs ...... with tolerance and dependence.
@en
Resting and evoked spinal subs ...... with tolerance and dependence.
@nl
type
label
Resting and evoked spinal subs ...... with tolerance and dependence.
@en
Resting and evoked spinal subs ...... with tolerance and dependence.
@nl
prefLabel
Resting and evoked spinal subs ...... with tolerance and dependence.
@en
Resting and evoked spinal subs ...... with tolerance and dependence.
@nl
P2093
P356
P1476
Resting and evoked spinal subs ...... with tolerance and dependence.
@en
P2093
Ichiro Kondo
Tony L Yaksh
Xiao-Ying Hua
P304
P356
10.1124/JPET.105.087718
P407
P577
2005-05-20T00:00:00Z